

Daniela Traini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5828512/daniela-traini-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

233
papers

4,979
citations

39
h-index

55
g-index

251
ext. papers

5,724
ext. citations

5.2
avg, IF

5.84
L-index

#	Paper	IF	Citations
233	Timothy Grass Pollen Induces Spatial Reorganisation of F-Actin and Loss of Junctional Integrity in Respiratory Cells.. <i>Inflammation</i> , 2022 , 1	5.1	0
232	Prospective nanoparticle treatments for lymphangi leiomyomatosis.. <i>Expert Opinion on Drug Delivery</i> , 2022 , 1-12	8	1
231	Combining experimental and computational techniques to understand and improve dry powder inhalers.. <i>Expert Opinion on Drug Delivery</i> , 2022 ,	8	1
230	An adaptable microreactor to investigate the influence of interfaces on Pseudomonas aeruginosa biofilm growth.. <i>Applied Microbiology and Biotechnology</i> , 2022 , 1	5.7	0
229	Toxicity of curcumin nanoparticles towards alveolar macrophage: Effects of surface charges.. <i>Food and Chemical Toxicology</i> , 2022 , 163, 112976	4.7	2
228	The application of in vitro cellular assays for analysis of electronic cigarettes impact on the airway.. <i>Life Sciences</i> , 2022 , 120487	6.8	
227	Investigating Potential TRPV1 Positive Feedback to Explain TRPV1 Upregulation in Airway Disease States.. <i>Drug Development and Industrial Pharmacy</i> , 2022 , 1-42	3.6	
226	Development and in vitro characterization of a novel pMDI diclofenac formulation as an inhalable anti-inflammatory therapy for cystic fibrosis. <i>International Journal of Pharmaceutics</i> , 2021 , 596, 120319	6.5	1
225	Co-delivery of inhalable therapies: Controlling active ingredients spatial distribution and temporal release. <i>Materials Science and Engineering C</i> , 2021 , 122, 111831	8.3	0
224	Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. <i>European Journal of Pharmacology</i> , 2021 , 902, 174098	5.3	0
223	In-vitro and particle image velocimetry studies of dry powder inhalers. <i>International Journal of Pharmaceutics</i> , 2021 , 592, 119966	6.5	7
222	Characterization of Negative Allosteric Modulators of the Calcium-Sensing Receptor for Repurposing as a Treatment of Asthma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 376, 51-63	4.7	2
221	Real-time quantitative monitoring of nasal drug delivery by a nasal epithelial mucosa-on-a-chip model. <i>Expert Opinion on Drug Delivery</i> , 2021 , 18, 803-818	8	5
220	On the Use of Computational Fluid Dynamics (CFD) Modelling to Design Improved Dry Powder Inhalers. <i>Pharmaceutical Research</i> , 2021 , 38, 277-288	4.5	2
219	How Do Mechanics Guide Fibroblast Activity? Complex Disruptions during Emphysema Shape Cellular Responses and Limit Research. <i>Bioengineering</i> , 2021 , 8,	5.3	1
218	Development and in vitro-in vivo performances of an inhalable indole-3-carboxaldehyde dry powder to target pulmonary inflammation and infection. <i>International Journal of Pharmaceutics</i> , 2021 , 607, 121004	6.5	4
217	Using individualized three-dimensional printed airway models to guide airway stent implantation. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020 , 31, 900-903	1.8	1

216	Advances in the use of cell penetrating peptides for respiratory drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2020 , 17, 647-664	8	7
215	Effect of continuous positive airway pressure treatment on permeability, inflammation and mucus production of human epithelial cells. <i>ERJ Open Research</i> , 2020 , 6,	3.5	3
214	Delivery of pDNA to lung epithelial cells using PLGA nanoparticles formulated with a cell-penetrating peptide: understanding the intracellular fate. <i>Drug Development and Industrial Pharmacy</i> , 2020 , 46, 427-442	3.6	6
213	Development and Evaluation of Paclitaxel and Curcumin Dry Powder for Inhalation Lung Cancer Treatment. <i>Pharmaceutics</i> , 2020 , 13,	6.4	8
212	Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioliomyomatosis. <i>European Journal of Pharmaceutical Sciences</i> , 2020 , 142, 105098	5.1	11
211	Selective shape-change response by anisotropic endoskeletal droplets. <i>Extreme Mechanics Letters</i> , 2020 , 35, 100618	3.9	1
210	An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020 , 156, 121-130	5.7	5
209	Modifying and Integrating and Respiratory Models for Inhalation Drug Screening. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020 , 8, 581995	5.8	10
208	Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size. <i>Nanomedicine</i> , 2020 , 15, 1927-1945	5.6	2
207	Nasal Powder Formulation of Tranexamic Acid and Hyaluronic Acid for the Treatment of Epistaxis. <i>Pharmaceutical Research</i> , 2020 , 37, 186	4.5	2
206	Paclitaxel-eluting silicone airway stent for preventing granulation tissue growth and lung cancer relapse in central airway pathologies. <i>Expert Opinion on Drug Delivery</i> , 2020 , 17, 1631-1645	8	3
205	Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part II: the effect of nanoparticle charge. <i>Nanomedicine</i> , 2020 , 15, 1947-1963	5.6	5
204	Nanotoxicologic Effects of PLGA Nanoparticles Formulated with a Cell-Penetrating Peptide: Searching for a Safe pDNA Delivery System for the Lungs. <i>Pharmaceutics</i> , 2019 , 11,	6.4	13
203	Application of a Thermosensitive In Situ Gel of Chitosan-Based Nasal Spray Loaded with Tranexamic Acid for Localised Treatment of Nasal Wounds. <i>AAPS PharmSciTech</i> , 2019 , 20, 299	3.9	17
202	Simvastatin Nanoparticles Reduce Inflammation in LPS-Stimulated Alveolar Macrophages. <i>Journal of Pharmaceutical Sciences</i> , 2019 , 108, 3890-3897	3.9	5
201	Assessing Aerosol Performance of a Dry Powder Carrier Formulation with Increasing Doses Using a Novel Inhaler. <i>AAPS PharmSciTech</i> , 2019 , 20, 94	3.9	5
200	Human Stimulus Factor Is a Promising Peptide for Delivery of Therapeutics. <i>Journal of Pharmaceutical Sciences</i> , 2019 , 108, 1401-1403	3.9	2
199	Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders. <i>Expert Opinion on Drug Delivery</i> , 2019 , 16, 453-466	8	37

198	Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes. <i>Pharmaceutics</i> , 2019 , 11,	6.4	87
197	Bronchial epithelial cell extracellular vesicles ameliorate epithelial-mesenchymal transition in COPD pathogenesis by alleviating M2 macrophage polarization. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019 , 18, 259-271	6	30
196	Co-Spray-Dried Urea Cross-Linked Hyaluronic Acid and Sodium Ascorbyl Phosphate as Novel Inhalable Dry Powder Formulation. <i>Journal of Pharmaceutical Sciences</i> , 2019 , 108, 2964-2971	3.9	6
195	An automated segmentation framework for nasal computational fluid dynamics analysis in computed tomography. <i>Computers in Biology and Medicine</i> , 2019 , 115, 103505	7	5
194	The utility of 3D-printed airway stents to improve treatment strategies for central airway obstructions. <i>Drug Development and Industrial Pharmacy</i> , 2019 , 45, 1-10	3.6	22
193	Effect of Dosing Cup Size on the Aerosol Performance of High-Dose Carrier-Based Formulations in a Novel Dry Powder Inhaler. <i>Journal of Pharmaceutical Sciences</i> , 2019 , 108, 949-959	3.9	3
192	In vitro characterization of physico-chemical properties, cytotoxicity, bioactivity of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate nasal powder formulation. <i>International Journal of Pharmaceutics</i> , 2019 , 558, 341-350	6.5	5
191	Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018 , 127, 250-259	5.7	45
190	Limitations of high dose carrier based formulations. <i>International Journal of Pharmaceutics</i> , 2018 , 544, 141-152	6.5	11
189	The use of fatty acids as absorption enhancer for pulmonary drug delivery. <i>International Journal of Pharmaceutics</i> , 2018 , 541, 93-100	6.5	15
188	Microfluidic production of endoskeleton droplets with controlled size and shape. <i>Powder Technology</i> , 2018 , 329, 129-136	5.2	11
187	Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection. <i>Pharmaceutical Research</i> , 2018 , 35, 50	4.5	10
186	Combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate for the treatment of inflammatory lung diseases: An in vitro study. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 120, 96-106	5.1	13
185	Repurposing of statins via inhalation to treat lung inflammatory conditions. <i>Advanced Drug Delivery Reviews</i> , 2018 , 133, 93-106	18.5	16
184	The Development and Validation of an In Vitro Airway Model to Assess Realistic Airway Deposition and Drug Permeation Behavior of Orally Inhaled Products Across Synthetic Membranes. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2018 , 31, 103-108	3.8	2
183	Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer. <i>Pharmaceutical Research</i> , 2018 , 36, 14	4.5	1
182	Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?. <i>Expert Opinion on Orphan Drugs</i> , 2018 , 6, 69-84	1.1	2
181	A Simple and Rapid Method for Deposition and Measurement of Drug Transport Across Air Interface Respiratory Epithelia. <i>AAPS PharmSciTech</i> , 2018 , 19, 3272-3276	3.9	2

180	The potential to treat lung cancer via inhalation of repurposed drugs. <i>Advanced Drug Delivery Reviews</i> , 2018 , 133, 107-130	18.5	39
179	Development of ciprofloxacin-loaded poly(vinyl alcohol) dry powder formulations for lung delivery. <i>International Journal of Pharmaceutics</i> , 2018 , 547, 114-121	6.5	10
178	Dosing challenges in respiratory therapies. <i>International Journal of Pharmaceutics</i> , 2018 , 548, 659-671	6.5	14
177	High-Speed Laser Image Analysis of Plume Angles for Pressurised Metered Dose Inhalers: The Effect of Nozzle Geometry. <i>AAPS PharmSciTech</i> , 2017 , 18, 782-789	3.9	11
176	Investigation into the Manufacture and Properties of Inhalable High-Dose Dry Powders Produced by Comilling API and Lactose with Magnesium Stearate. <i>AAPS PharmSciTech</i> , 2017 , 18, 2248-2259	3.9	4
175	Co-milled API-lactose systems for inhalation therapy: impact of magnesium stearate on physico-chemical stability and aerosolization performance. <i>Drug Development and Industrial Pharmacy</i> , 2017 , 43, 980-988	3.6	14
174	Allergic environment enhances airway epithelial pro-inflammatory responses to rhinovirus infection. <i>Clinical Science</i> , 2017 , 131, 499-509	6.5	14
173	Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery. <i>Drug Development and Industrial Pharmacy</i> , 2017 , 43, 1510-1518	3.6	16
172	The effect of non-specific tight junction modulators on the transepithelial transport of poorly permeable drugs across airway epithelial cells. <i>Journal of Drug Targeting</i> , 2017 , 25, 342-349	5.4	4
171	A review of co-milling techniques for the production of high dose dry powder inhaler formulation. <i>Drug Development and Industrial Pharmacy</i> , 2017 , 43, 1229-1238	3.6	16
170	Revealing pMDI Spray Initial Conditions: Flashing, Atomisation and the Effect of Ethanol. <i>Pharmaceutical Research</i> , 2017 , 34, 718-729	4.5	10
169	The Development and Achievement of Polymeric Nanoparticles for Cancer Drug Treatment 2017 , 25-82		1
168	Inhaled simvastatin nanoparticles for inflammatory lung disease. <i>Nanomedicine</i> , 2017 , 12, 2471-2485	5.6	8
167	The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer. <i>Expert Opinion on Drug Delivery</i> , 2017 , 14, 937-957	8	20
166	Inhaled gene delivery: a formulation and delivery approach. <i>Expert Opinion on Drug Delivery</i> , 2017 , 14, 319-330	8	24
165	Novel nano-cellulose excipient for generating non-Newtonian droplets for targeted nasal drug delivery. <i>Drug Development and Industrial Pharmacy</i> , 2017 , 43, 1729-1733	3.6	4
164	Curcumin Nanoparticles Attenuate Production of Pro-inflammatory Markers in Lipopolysaccharide-Induced Macrophages. <i>Pharmaceutical Research</i> , 2016 , 33, 315-27	4.5	10
163	Biological Effects of Simvastatin Formulated as pMDI on Pulmonary Epithelial Cells. <i>Pharmaceutical Research</i> , 2016 , 33, 92-101	4.5	15

162	Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016 , 107, 223-33	5.7	36
161	Synthesis and Characterization of Inhalable Flavonoid Nanoparticle for Lung Cancer Cell Targeting. <i>Journal of Biomedical Nanotechnology</i> , 2016 , 12, 371-86	4	27
160	Effect of polyunsaturated fatty acids (PUFAs) on airway epithelial cells tight junction. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016 , 40, 30-8	3.5	8
159	Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and in vitro deposition study. <i>Journal of Microencapsulation</i> , 2016 , 33, 735-742	3.4	11
158	Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons. <i>Expert Opinion on Drug Delivery</i> , 2016 , 13, 1407-20	8	10
157	Primary Air-Liquid Interface Culture of Nasal Epithelium for Nasal Drug Delivery. <i>Molecular Pharmaceutics</i> , 2016 , 13, 2242-52	5.6	24
156	Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability. <i>Expert Opinion on Drug Delivery</i> , 2016 , 13, 183-93	8	22
155	Antibiotic transport across bronchial epithelial cells: Effects of molecular weight, LogP and apparent permeability. <i>European Journal of Pharmaceutical Sciences</i> , 2016 , 83, 45-51	5.1	11
154	Knowledge that people with intellectual disabilities have of their inhaled asthma medications: messages for pharmacists. <i>International Journal of Clinical Pharmacy</i> , 2016 , 38, 135-43	2.3	14
153	Insights into Spray Development from Metered-Dose Inhalers Through Quantitative X-ray Radiography. <i>Pharmaceutical Research</i> , 2016 , 33, 1249-58	4.5	6
152	The ability of people with intellectual disability to use inhalers--an exploratory mixed methods study. <i>Journal of Asthma</i> , 2016 , 53, 86-93	1.9	6
151	Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages. <i>European Journal of Pharmaceutical Sciences</i> , 2016 , 86, 20-8 ^{5.1}	5.1	28
150	Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation. <i>Drug Development and Industrial Pharmacy</i> , 2016 , 42, 1660-8	3.6	22
149	Combination of Silver Nanoparticles and Curcumin Nanoparticles for Enhanced Anti-biofilm Activities. <i>Journal of Agricultural and Food Chemistry</i> , 2016 , 64, 2513-22	5.7	107
148	Temporally and Spatially Resolved x-ray Fluorescence Measurements of in-situ Drug Concentration in Metered-Dose Inhaler Sprays. <i>Pharmaceutical Research</i> , 2016 , 33, 816-25	4.5	9
147	Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 375-87	5.4	21
146	Exploring the impact of sample flowrate on in vitro measurements of metered dose inhaler performance. <i>International Journal of Pharmaceutics</i> , 2016 , 514, 420-427	6.5	3
145	An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy. <i>RSC Advances</i> , 2016 , 6, 25789-25798	3.7	11

144	The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis. <i>International Journal of Pharmaceutics</i> , 2016 , 514, 392-398	6.5	16
143	Evolved gas analysis during thermal degradation of salbutamol sulphate. <i>Journal of Thermal Analysis and Calorimetry</i> , 2015 , 120, 789-794	4.1	3
142	Mono- and Cocultures of Bronchial and Alveolar Epithelial Cells Respond Differently to Proinflammatory Stimuli and Their Modulation by Salbutamol and Budesonide. <i>Molecular Pharmaceutics</i> , 2015 , 12, 2625-32	5.6	9
141	In vitro biological activity of resveratrol using a novel inhalable resveratrol spray-dried formulation. <i>International Journal of Pharmaceutics</i> , 2015 , 491, 190-7	6.5	22
140	Determination of physical and chemical stability in pressurised metered dose inhalers: potential new techniques. <i>Expert Opinion on Drug Delivery</i> , 2015 , 12, 1661-75	8	5
139	Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015 , 93, 320-7	5.7	15
138	Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection. <i>Molecular Pharmaceutics</i> , 2015 , 12, 2001-9	5.6	31
137	Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler. <i>Pharmaceutical Research</i> , 2015 , 32, 2144-53	4.5	9
136	The Effect of Active Pharmaceutical Ingredients on Aerosol Electrostatic Charges from Pressurized Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2015 , 32, 2928-36	4.5	4
135	Tuning aerosol performance using the multibreath Orbital [®] dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry. <i>Journal of Pharmaceutical Sciences</i> , 2015 , 104, 2169-76	3.9	11
134	Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages. <i>Expert Opinion on Drug Delivery</i> , 2015 , 12, 1009-26	8	88
133	Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges. <i>Asian Journal of Pharmaceutical Sciences</i> , 2015 , 10, 481-489	9	98
132	An Investigation into the Powder Release Behavior from Capsule-Based Dry Powder Inhalers. <i>Aerosol Science and Technology</i> , 2015 , 49, 902-911	3.4	5
131	Delivery of theophylline as dry powder for inhalation. <i>Asian Journal of Pharmaceutical Sciences</i> , 2015 , 10, 520-527	9	12
130	Solid lipid microparticles as an approach to drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2015 , 12, 583-89		57
129	Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. <i>Drug Development and Industrial Pharmacy</i> , 2015 , 41, 859-65	3.6	19
128	Aerosol particle generation from solution-based pressurized metered dose inhalers: a technical overview of parameters that influence respiratory deposition. <i>Pharmaceutical Development and Technology</i> , 2015 , 20, 897-910	3.4	11
127	The effect of actuator nozzle designs on the electrostatic charge generated in pressurised metered dose inhaler aerosols. <i>Pharmaceutical Research</i> , 2015 , 32, 1237-48	4.5	3

126	Dry powder formulation of simvastatin. <i>Expert Opinion on Drug Delivery</i> , 2015 , 12, 857-68	8	17
125	The role of direct support professionals in asthma management. <i>Journal of Intellectual and Developmental Disability</i> , 2015 , 40, 342-353	1.9	11
124	Unique location but similar issues: working with health professionals in correctional services to improve inhaler use. <i>Journal of Pharmacy Practice and Research</i> , 2015 , 45, 276-281	0.7	
123	The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices. <i>Current Drug Delivery</i> , 2015 , 12, 40-6	3.2	1
122	The formulation of a pressurized metered dose inhaler containing theophylline for inhalation. <i>European Journal of Pharmaceutical Sciences</i> , 2015 , 76, 68-72	5.1	13
121	Inhalable tranexamic acid for haemoptysis treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015 , 93, 311-9	5.7	11
120	Beating cilia identification in fluorescence microscope images for accurate CBF measurement 2015 ,		1
119	The Formation of Aerosol Particles from Solution-Based Pressurized Metered Dose Inhalers and Implications of Incomplete Droplet Drying: Theoretical and Experimental Comparison. <i>Aerosol Science and Technology</i> , 2015 , 49, 1090-1099	3.4	3
118	Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 319-23	14.3	8
117	A Soft spot for drug transport: modulation of cell stiffness using fatty acids and its impact on drug transport in lung model. <i>Journal of Materials Chemistry B</i> , 2015 , 3, 2583-2589	7.3	12
116	Motion Representation of Ciliated Cell Images with Contour-Alignment for Automated CBF Estimation. <i>Lecture Notes in Computer Science</i> , 2015 , 300-307	0.9	
115	Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases. <i>AAPS Journal</i> , 2014 , 16, 269-80	3.7	21
114	In vitro cell integrated impactor deposition methodology for the study of aerodynamically relevant size fractions from commercial pressurised metered dose inhalers. <i>Pharmaceutical Research</i> , 2014 , 31, 1779-87	4.5	25
113	A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. <i>Pharmaceutical Research</i> , 2014 , 31, 1239-53	4.5	36
112	Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations. <i>Pharmacology & Therapeutics</i> , 2014 , 144, 235-52	13.9	44
111	Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. <i>Pharmaceutical Development and Technology</i> , 2014 , 19, 911-21	3.4	7
110	Image-based ciliary beating frequency estimation for therapeutic assessment on defective mucociliary clearance diseases 2014 ,		2
109	An update on the use of rifapentine for tuberculosis therapy. <i>Expert Opinion on Drug Delivery</i> , 2014 , 11, 421-31	8	22

108	A novel high-speed imaging technique to predict the macroscopic spray characteristics of solution based pressurised metered dose inhalers. <i>Pharmaceutical Research</i> , 2014 , 31, 2963-74	4.5	9
107	Novel simvastatin inhalation formulation and characterisation. <i>AAPS PharmSciTech</i> , 2014 , 15, 956-62	3.9	16
106	Recent advances in curcumin nanoformulation for cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2014 , 11, 1183-201	8	157
105	Isothermal calorimetry: a predictive tool to model drug-propellant interactions in pressurized metered dose systems. <i>International Journal of Pharmaceutics</i> , 2014 , 461, 301-9	6.5	12
104	A novel inhalable form of rifapentine. <i>Journal of Pharmaceutical Sciences</i> , 2014 , 103, 1411-21	3.9	32
103	In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014 , 86, 83-9	5.7	39
102	The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. <i>Journal of Pharmacy and Pharmacology</i> , 2014 , 66, 639-45	4.8	8
101	Graphing software for medical writers. <i>Medical Writing</i> , 2014 , 23, 41-44		1
100	Overcoming dose limitations using the orbital(□) multi-breath dry powder inhaler. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2014 , 27, 138-47	3.8	37
99	Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014 , 86, 38-45	5.7	18
98	The solid-state and morphological characteristics of particles generated from solution-based metered dose inhalers: Influence of ethanol concentration and intrinsic drug properties. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2014 , 443, 345-355	5.1	14
97	Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014 , 86, 31-7	5.7	21
96	Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline. <i>Drug Delivery and Translational Research</i> , 2014 , 4, 256-67	6.2	7
95	The influence of actuator materials and nozzle designs on electrostatic charge of pressurised metered dose inhaler (pMDI) formulations. <i>Pharmaceutical Research</i> , 2014 , 31, 1325-37	4.5	7
94	Respiratory medication use in an Australian developmental disability clinic population: messages for health care professionals. <i>Australian Journal of Primary Health</i> , 2014 , 20, 278-84	1.4	10
93	Comparison of spray congealing and melt emulsification methods for the incorporation of the water-soluble salbutamol sulphate in lipid microparticles. <i>Pharmaceutical Development and Technology</i> , 2013 , 18, 266-73	3.4	11
92	The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. <i>Drug Development and Industrial Pharmacy</i> , 2013 , 39, 1625-37	3.6	24
91	Pharmaceutical applications of the Calu-3 lung epithelia cell line. <i>Expert Opinion on Drug Delivery</i> , 2013 , 10, 1287-302	8	49

90	Salbutamol sulfate absorption across Calu-3 bronchial epithelia cell monolayer is inhibited in the presence of common anionic NSAIDs. <i>Journal of Asthma</i> , 2013 , 50, 334-41	1.9	18
89	Quality of Inhalation Products: Specifications 2013 , 169-190		1
88	Aerodynamic Assessment for Inhalation Products: Fundamentals and Current Pharmacopoeial Methods 2013 , 91-119		7
87	Inhalation Drug Delivery 2013 , 1-14		5
86	Inhalation and Nasal Products 2013 , 15-30		0
85	Formulation of Inhalation Medicines 2013 , 31-45		3
84	Methods for Understanding, Controlling, Predicting, and Improving Drug Product Performance 2013 , 63-89		
83	Novel Particle Production Technologies for Inhalation Products 2013 , 47-62		4
82	Proteins, Peptides, and Controlled-Release Formulations for Inhalation 2013 , 121-144		1
81	Pharmaceutical development studies for inhalation products 2013 , 145-168		
80	Quercetin solid lipid microparticles: a flavonoid for inhalation lung delivery. <i>European Journal of Pharmaceutical Sciences</i> , 2013 , 49, 278-85	5.1	44
79	The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia. <i>Molecular Pharmaceutics</i> , 2013 , 10, 2915-24	5.6	21
78	A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013 , 83, 285-92	5.7	70
77	Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013 , 84, 566-72	5.7	20
76	Incorporation of quercetin in respirable lipid microparticles: effect on stability and cellular uptake on A549 pulmonary alveolar epithelial cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2013 , 112, 322-9	6	15
75	Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2535-40	5.9	37
74	Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler. <i>Respirology</i> , 2013 , 18, 1197-201	3.6	19
73	Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers. <i>Journal of Pharmacy and Pharmacology</i> , 2012 , 64, 1245-53	4.8	15

72	Twenty years of HFA pMDI patents: facts and perspectives. <i>Journal of Pharmacy and Pharmacology</i> , 2012 , 64, 1209-16	4.8	5
71	Micronized drug powders in binary mixtures and the effect of physical properties on aerosolization from combination drug dry powder inhalers. <i>Drug Development and Industrial Pharmacy</i> , 2012 , 38, 1504-11	3.6	6
70	Modification of disodium cromoglycate passage across lung epithelium in vitro via incorporation into polymeric microparticles. <i>AAPS Journal</i> , 2012 , 14, 79-86	3.7	4
69	Magnetised thermo responsive lipid vehicles for targeted and controlled lung drug delivery. <i>Pharmaceutical Research</i> , 2012 , 29, 2456-67	4.5	41
68	Polymer coating of carrier excipients modify aerosol performance of adhered drugs used in dry powder inhalation therapy. <i>International Journal of Pharmaceutics</i> , 2012 , 438, 150-9	6.5	17
67	Preparation and in vitro evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy. <i>Journal of Microencapsulation</i> , 2012 , 29, 225-33	3.4	19
66	Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia. <i>Molecular Pharmaceutics</i> , 2012 , 9, 1717-26	5.6	44
65	Preparation and evaluation of single and co-engineered combination inhalation carrier formulations for the treatment of asthma. <i>Journal of Pharmaceutical Sciences</i> , 2012 , 101, 4267-76	3.9	3
64	Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. <i>Pharmaceutical Research</i> , 2012 , 29, 3335-46	4.5	63
63	The use of computational approaches in inhaler development. <i>Advanced Drug Delivery Reviews</i> , 2012 , 64, 312-22	18.5	54
62	The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers. <i>Advanced Drug Delivery Reviews</i> , 2012 , 64, 285-93	18.5	39
61	Delivery of high solubility polyols by vibrating mesh nebulizer to enhance mucociliary clearance. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012 , 25, 297-305	3.8	11
60	Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1913-32	4	14
59	A Review of Electrostatic Measurement Techniques for Aerosol Drug Delivery to the Lung: Implications in Aerosol Particle Deposition. <i>Journal of Adhesion Science and Technology</i> , 2011 , 25, 385-403	3	12
58	Modelling of molecular phase transitions in pharmaceutical inhalation compounds: an in silico approach. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011 , 78, 83-9	5.7	14
57	Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. <i>Expert Opinion on Drug Delivery</i> , 2011 , 8, 1205-20	8	35
56	The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers. <i>International Journal of Pharmaceutics</i> , 2011 , 416, 129-35	6.5	39
55	Epithelial profiling of antibiotic controlled release respiratory formulations. <i>Pharmaceutical Research</i> , 2011 , 28, 2327-38	4.5	40

54	Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems. <i>International Journal of Pharmaceutics</i> , 2011 , 413, 1-9	6.5	35
53	Mannitol delivery by vibrating mesh nebulisation for enhancing mucociliary clearance. <i>Journal of Pharmaceutical Sciences</i> , 2011 , 100, 2693-702	3.9	11
52	Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of impaction effects for agglomerated systems. <i>Journal of Pharmaceutical Sciences</i> , 2011 , 100, 2744-54	3.9	19
51	Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of the influence of grid structures for agglomerated systems. <i>Journal of Pharmaceutical Sciences</i> , 2011 , 100, 4710-21	3.9	21
50	Aerosol tribocharging and its relation to the deposition of Oxis [®] Turbuhaler [®] in the electrical next generation impactor. <i>Journal of Pharmaceutical Sciences</i> , 2011 , 100, 5270-80	3.9	4
49	Particle synergy and aerosol performance in non-aqueous liquid of two combinations metered dose inhalation formulations: an AFM and Raman investigation. <i>Journal of Colloid and Interface Science</i> , 2011 , 361, 649-55	9.3	23
48	Dynamic electrostatic charge of lactose-salbutamol sulphate powder blends dispersed from a Cyclohaler [®] . <i>Drug Development and Industrial Pharmacy</i> , 2011 , 37, 1365-75	3.6	6
47	Controlled release antibiotics for dry powder lung delivery. <i>Drug Development and Industrial Pharmacy</i> , 2010 , 36, 119-26	3.6	45
46	Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. <i>Drug Development and Industrial Pharmacy</i> , 2010 , 36, 1207-14	3.6	86
45	The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems. <i>Pharmaceutical Research</i> , 2010 , 27, 1325-36	4.5	15
44	Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems. <i>Pharmaceutical Research</i> , 2010 , 27, 1367-76	4.5	41
43	Artesunate-clindamycin multi-kinetics and site-specific oral delivery system for antimalaric combination products. <i>Journal of Controlled Release</i> , 2010 , 146, 54-60	11.7	15
42	Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. <i>European Journal of Pharmaceutical Sciences</i> , 2010 , 40, 239-47	5.1	78
41	Does electrostatic charge affect powder aerosolisation?. <i>Journal of Pharmaceutical Sciences</i> , 2010 , 99, 2455-61	3.9	21
40	Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010 , 51, 853-7	3.5	22
39	Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI). <i>European Journal of Pharmaceutical Sciences</i> , 2009 , 38, 88-94	5.1	41
38	Preparation and evaluation of controlled release microparticles for respiratory protein therapy. <i>Journal of Pharmaceutical Sciences</i> , 2009 , 98, 2709-17	3.9	31
37	Introduction of the electrical next generation impactor (eNGI) and investigation of its capabilities for the study of pressurized metered dose inhalers. <i>Pharmaceutical Research</i> , 2009 , 26, 431-7	4.5	26

36	Lactose composite carriers for respiratory delivery. <i>Pharmaceutical Research</i> , 2009 , 26, 802-10	4.5	47
35	Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. <i>Pharmaceutical Research</i> , 2009 , 26, 1084-92	4.5	47
34	The influence of flow rate on the aerosol deposition profile and electrostatic charge of single and combination metered dose inhalers. <i>Pharmaceutical Research</i> , 2009 , 26, 2639-46	4.5	34
33	Development of an in vivo ovine dry powder inhalation model for the evaluation of conventional and controlled release microparticles. <i>AAPS Journal</i> , 2009 , 11, 465-8	3.7	6
32	Solid lipid budesonide microparticles for controlled release inhalation therapy. <i>AAPS Journal</i> , 2009 , 11, 771-8	3.7	54
31	The influence of micronised particulates on the aerosolisation properties of pressurised metered dose inhalers. <i>Journal of Aerosol Science</i> , 2009 , 40, 324-337	4.3	9
30	Delivery of antibiotics to the respiratory tract: an update. <i>Expert Opinion on Drug Delivery</i> , 2009 , 6, 897-905		70
29	Recent advances in controlled release pulmonary therapy. <i>Current Drug Delivery</i> , 2009 , 6, 404-14	3.2	19
28	Micro-particle corrugation, adhesion and inhalation aerosol efficiency. <i>European Journal of Pharmaceutical Sciences</i> , 2008 , 35, 12-8	5.1	74
27	The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations. <i>Drug Development and Industrial Pharmacy</i> , 2008 , 34, 992-1001	3.6	83
26	Composite carriers improve the aerosolisation efficiency of drugs for respiratory delivery. <i>Journal of Aerosol Science</i> , 2008 , 39, 82-93	4.3	36
25	Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 1: influence of polymer concentration on physical and in vitro characteristics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008 , 69, 486-95	5.7	32
24	Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008 , 70, 145-52	5.7	77
23	Scanning white-light interferometry as a novel technique to quantify the surface roughness of micron-sized particles for inhalation. <i>Langmuir</i> , 2008 , 24, 11307-12	4	22
22	The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. <i>Journal of Pharmaceutical Sciences</i> , 2008 , 97, 2780-8	3.9	64
21	Role of agglomeration in the dispersion of salmeterol xinafoate from mixtures for inhalation with differing drug to fine lactose ratios. <i>Journal of Pharmaceutical Sciences</i> , 2008 , 97, 3140-52	3.9	33
20	Cospray dried antibiotics for dry powder lung delivery. <i>Journal of Pharmaceutical Sciences</i> , 2008 , 97, 3356-66		60
19	The use of atomic force microscopy to study the conditioning of micronised budesonide. <i>International Journal of Pharmaceutics</i> , 2008 , 357, 314-7	6.5	10

18	Microstructural analysis of porous composite materials: dynamic imaging of drug dissolution and diffusion through porous matrices. <i>AAPS Journal</i> , 2008 , 10, 560-4	3.7	7
17	Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy. <i>AAPS PharmSciTech</i> , 2008 , 9, 605-11	3.9	2
16	The nanoscale in pulmonary delivery. Part 2: formulation platforms. <i>Expert Opinion on Drug Delivery</i> , 2007 , 4, 607-20	8	44
15	The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. <i>Expert Opinion on Drug Delivery</i> , 2007 , 4, 595-606	8	91
14	The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. <i>Journal of Pharmaceutical Sciences</i> , 2007 , 96, 1331-41	3.9	53
13	Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems. <i>Pharmaceutical Research</i> , 2007 , 24, 963-70	4.5	85
12	Recent advances in understanding the influence of composite-formulation properties on the performance of dry powder inhalers. <i>Physica B: Condensed Matter</i> , 2007 , 394, 315-319	2.8	8
11	The use of organic vapor sorption to determine low levels of amorphous content in processed pharmaceutical powders. <i>Drug Development and Industrial Pharmacy</i> , 2007 , 33, 91-7	3.6	39
10	Effect of moisture on the compressibility and compactibility of sodium starch glycolate. <i>Pharmaceutical Development and Technology</i> , 2007 , 12, 217-22	3.4	2
9	In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers. <i>Pharmaceutical Research</i> , 2007 , 24, 125-35	4.5	28
8	Comparative study of erythritol and lactose monohydrate as carriers for inhalation: atomic force microscopy and in vitro correlation. <i>European Journal of Pharmaceutical Sciences</i> , 2006 , 27, 243-51	5.1	32
7	The Use of AFM and Surface Energy Measurements to Investigate Drug-Canister Material Interactions in a Model Pressurized Metered Dose Inhaler Formulation. <i>Aerosol Science and Technology</i> , 2006 , 40, 227-236	3.4	24
6	A novel apparatus for the determination of solubility in pressurized metered dose inhalers. <i>Drug Development and Industrial Pharmacy</i> , 2006 , 32, 1159-63	3.6	14
5	Investigation into the influence of polymeric stabilizing excipients on inter-particulate forces in pressurised metered dose inhalers. <i>International Journal of Pharmaceutics</i> , 2006 , 320, 58-63	6.5	24
4	Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation. <i>Pharmaceutical Research</i> , 2006 , 23, 2556-65	4.5	71
3	The influence of dose on the performance of dry powder inhalation systems. <i>International Journal of Pharmaceutics</i> , 2005 , 296, 26-33	6.5	90
2	Surface energy and interparticle forces correlations in model pMDI formulations. <i>Pharmaceutical Research</i> , 2005 , 22, 816-25	4.5	47
1	Under pressure: predicting pressurized metered dose inhaler interactions using the atomic force microscope. <i>Journal of Colloid and Interface Science</i> , 2003 , 262, 298-302	9.3	39

